{"id":"W3088134494","doi":"10.1016/j.annonc.2020.08.1004","title":"865P A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Ipsen; Clovis Oncology; Regeneron Pharmaceuticals; GlaxoSmithKline; Louisiana State University; Spectrum Pharmaceuticals; Takeda Oncology; Amgen; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; King Abdullah International Medical Research Center; U.S. Department of Defense","keywords":"Medicine; Internal medicine; Progressive disease; Clinical endpoint; Oncology; Chemotherapy; Cancer; Response Evaluation Criteria in Solid Tumors; Cervical cancer; Adenosquamous carcinoma; Gastroenterology; Progression-free survival; Adenocarcinoma; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007123431,0.0008896709,0.001352527,0.0003150086,0.0003472854,0.0006985448,0.0005144035,0.0006568187,0.005163149],"category_scores_gemma":[0.0004316671,0.0003243854,0.001247131,0.0003671387,0.0005886887,0.0004962828,0.000304921,0.001969415,0.001138842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008008071,"about_ca_system_score_gemma":0.001779312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002413547,"about_ca_topic_score_gemma":0.006625927,"domain_scores_codex":[0.9998133,0.00006885626,0.000009575161,0.00003432278,0.00001699315,0.00005699654],"domain_scores_gemma":[0.9997675,0.00002625841,0.00003599814,0.00001722642,0.00001945918,0.0001335932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7051167,0.02804046,0.01041086,0.001682516,0.002761634,0.0002794823,0.0003733369,0.003404558,0.03968652,0.0006778379,0.01083844,0.1967277],"study_design_scores_gemma":[0.6326988,0.3255393,0.02553689,0.00006820363,0.001680653,0.0003492747,0.0001701268,0.002321921,0.003725678,0.0003501494,0.007505423,0.00005346649],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920264,0.001439219,0.0002904041,0.0005438668,0.0001445136,0.001324068,0.001169285,0.0001049336,0.002957341],"genre_scores_gemma":[0.9871626,0.001943012,0.001024671,0.0008804627,0.0001012609,0.001106074,0.002827671,0.00002335335,0.00493088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005163149,"threshold_uncertainty_score":0.01727247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1653421335762386,"score_gpt":0.4479041455608715,"score_spread":0.2825620119846329,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}